AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03652025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: embolotherapy of incompetent gonadal and iliac veins
Description: minimally invasive
Study NCT04293315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improvement Cycles
Description: This is a multi-component intervention following the Institute for Healthcare Improvement (IHI)'s Collaborative Model for Achieving Breakthrough Improvement by implementing plan-do-study-act (PDSA) improvement cycles. The investigators will conduct 8 participative learning sessions for the primary care team. These sessions will be aimed at identifying opportunities for improvement oriented to the design and application of innovative approaches based on best practices.
Study NCT02628756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial injury
Description: Office hysteroscopy (Karl Storz, Tuttlingen, Germany)
Study NCT00172107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX1-11 50 mcg
Description: PTH(1-84) 50 mcg for subcutaneous injection into thigh or abdomen
Study NCT00172107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo powder for subcutaneous injection
Study NCT00172107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX1-11 75mcg
Description: PTH(1-84)75 mcg for subcutaneous injection
Study NCT02220543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary care as usual
Description: Regular physical therapy in primary care. Physical therapists are recommended by their profession (the Royal Dutch Society for Physical Therapy) to work according to a profession-specific guideline for the treatment of patients with low back pain in primary care settings. Maximally 12 individual sessions (30 minutes each) for a maximum of 8 weeks.
Study NCT02220543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary care as usual
Description: Regular physical therapy in primary care. Physical therapists are recommended by their profession (the Royal Dutch Society for Physical Therapy) to work according to a profession-specific guideline for the treatment of patients with low back pain in primary care settings. Maximally 12 individual sessions (30 minutes each) for a maximum of 8 weeks.
Study NCT00172107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX1-11
Description: PTH (1-84) 100mcg for subcutaneous injection into thigh or abdomen
Study NCT02902627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non Invasive Monitoring Device (ANI)
Description: Pain measure by ANI monitor and with visual analogical scale
Study NCT01906346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: Three active doses of cocaine will be made available for self-administration during experimental sessions.
Study NCT01906346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo cocaine will be made available for self-administration during experimental sessions.
Study NCT00334555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: different methods of partner notification
Description: comparing patient referral, partner delivered medications and field intervention to treat sex partners
Study NCT00334555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: partner delivered meds
Description: patient given meds to give to her partner
Study NCT00334555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: field intervention
Description: health worker finds partners
Study NCT02311946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib Alone
Description: In Period 1 of each Cohort, a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.
Study NCT02311946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib + Rabeprazole
Description: In Period 2 of each Cohort, subjects will receive daily 40 mg oral doses of the proton pump inhibitor rabeprazole on 7 consecutive days. Approximately 4 hours after the last rabeprazole dose a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.
Study NCT01444209 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iodine Implants
Description: Interstitial Radioactive Iodine Implants
Study NCT02172339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium, solution ampoules
Study NCT04021251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P0.2
Description: Investigational Medical Device collecting spectral raman data from tissue.
Study NCT02225353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone Cervical Pessary 6.3 g
Description: Progesterone Cervical Pessary low dose
Study NCT02225353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone 200 mg vaginal capsules
Description: Progesterone 200 mg vaginal capsules daily
Study NCT02225353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone Cervical Pessary 7.7 g
Description: Progesterone Cervical Pessary high dose
Study NCT02463643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-215 10mg
Description: Z-215 10mg, capsules
Study NCT02463643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-215 20mg
Description: Z-215 20mg, capsules
Study NCT02463643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Z-215 Placebo
Description: Z-215 placebo-matching capsules
Study NCT02463643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-215 Placebo
Description: Z-215 placebo-matching capsules
Study NCT02463643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole Sodium
Description: Rabeprazole Sodium 10mg tablets
Study NCT02463643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium Placebo
Description: Rabeprazole Sodium Placebo placebo-matching tablets
Study NCT01172509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-baclofen
Description: oral R-baclofen at 0x2, 3, 10, and 25 mg
Study NCT01172509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: R-baclofen
Description: oral R-baclofen at 0x2, 3, 10, and 25 mg
Study NCT03056911 — intervention group
Intervention type: DRUG
Intervention: Ozone
Description: Pain relief with chemonucleolysis by using ozone regard to age, sex, ASA score, and complications.
Study NCT02648750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bridges self-management programme
Description: The Bridges self-management programme is based on self-efficacy principles. It includes a Bridges stroke workbook consisting of stroke survivors' experiences and strategies, with space to record and reflect on personal goals and achievements, which the practitioner will work through with the participant. The practitioner will also used strategies based on key principles of self-management during interactions with patients.
Study NCT02648750 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bridges self-management programme
Description: The Bridges self-management programme is based on self-efficacy principles. It includes a Bridges stroke workbook consisting of stroke survivors' experiences and strategies, with space to record and reflect on personal goals and achievements, which the practitioner will work through with the participant. The practitioner will also used strategies based on key principles of self-management during interactions with patients.
Study NCT03501186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Backward walking on sand
Description: the patient will be walking backwards on sand with therapist standing close to support in case of fall.
Study NCT03501186 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Backward walking on sand
Description: the patient will be walking backwards on sand with therapist standing close to support in case of fall.
Study NCT01387919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged fasting
Description: 48 hours of fasting
Study NCT01013766 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK1362885
Description: 100mg in the AM, 100mg in the PM, 50mg BID
Study NCT01013766 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK1362885
Description: 100mg in the PM, 100mg in the AM, 50mg BID
Study NCT02374021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Subjects entering trial will continue on MTX dose of at least 15mg MTX/week. At the discretion of the treating rheumatologist, may be switched to SQ route.
Study NCT02374021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: 1 gm bid
Study NCT02374021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: 200 mg twice daily, not to exceed 6.5mg/kg
Study NCT02374021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: 50 mg SC weekly
Study NCT02374021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: 40 mg SQ every other week
Study NCT04727918 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Polypectomy of diminutive colorectal polyps will be performed by CBF
Description: All polypectomy procedures will be standardized amongst the study centers. Endoscopists with a minimal experience of at least 50 CBF and CSP performed the polypectomies CBF : The CBF will be performed using a standard biopsy forceps (Gluton Life ® Life Partners). Multiple biopsies bites were taken until complete resection (as many as needed).
Study NCT04727918 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Polypectomy of diminutive colorectal polyps will be performed by CSP
Description: All polypectomy procedures will be standardized amongst the study centers. Endoscopists with a minimal experience of at least 50 CBF and CSP performed the polypectomies CSP : The CSB procedure will be performed using a 9 mm cold snare (Exacto ® Life Partners). One to two mm of normal surrounding mucosa will be ensnared around the base of the polyp, followed by mechanical excision without electrocautery
Study NCT00225576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Implementation
Description: Intervention subjects implemented electronic prescribing as part of an electronic health record implementation
Study NCT06248346 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Description: whether intraoperative dexmedetomidine was administered adjunct to propofol for patients undergoing surgeries under general anaesthesia
Study NCT01144767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-generated advisor
Description: Weekly sessions with a computer generated advisor who offers advice, feedback and guidance on physical activity
Study NCT01144767 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison control condition
Description: Weekly/biweekly sessions with a group facilitator to receive health education and information.
Study NCT02790580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-dense doxorubicin/cyclophosphamide + sunitinib
Description: Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide Oral sunitinib 12.5mg daily for 7 days prior to cycle 1 ddAC (days -7 to 0) Oral sunitinib 12.5mg daily for 5 days prior to cycle 2, 3, 4 ddAC (days 10-14 of preceding cycle)~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease.
Study NCT02790580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dose-dense doxorubicin/cyclophosphamide
Description: Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease.
Study NCT01211743 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Standard 4 port laparoscopic cholecystectomy
Study NCT01211743 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single incision laparoscopic cholecystectomy
Description: One port placed through the umbilicus
Study NCT01276431 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Buprenorphine transdermal patch
Study NCT04017325 — intervention group
Intervention type: OTHER
Intervention: no intervention (post study follow up)
Description: No intervention (post study follow up)
Study NCT00736762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GPR
Description: The subjects randomised to the GPR program will participate in posture retraining techniques of approximately forty minutes, one time a week for ten weeks.
Study NCT00006461 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin
Description: Given IV
Study NCT00006461 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphamide
Description: Given IV
Study NCT00006461 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: vincristine sulfate
Description: Given IV
Study NCT00006461 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: etoposide
Description: Given PO
Study NCT03610165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acumen HPI-enabled EV1000 screen
Description: Acumen HPI-enabled EV1000 screen.
Study NCT03610165 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Arterial waveform and pressures
Study NCT03125213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AL-3778
Description: AL-3778 tablets
Study NCT03125213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon Alfa-2A
Description: Peginterferon Alfa-2A for subcutaneous injection
Study NCT03125213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon Alfa-2A
Description: Peginterferon Alfa-2A for subcutaneous injection
Study NCT03125213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo to Match AL-3778 tablet
Study NCT02802709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SB-061
Description: delivered via intra-articular injection
Study NCT02802709 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01088256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: the patients get etoricoxib 90mg for 8 days. They get one pill with 90mg per day
Study NCT01088256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients get one pill of placebo (sugar-pill) per day for 8 days.
Study NCT03744325 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hen's egg OIT
Description: Increasing doses of egg white protein administered orally
Study NCT04547673 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: rigid nasal endoscopes
Description: The endoscope is introduced through the nasal passage to observe, in sequence, the posterior nostril, superior and posterior walls of the nasopharynx, torus tubarius, pharyngeal opening of the auditory tube, and Rosenmu¨ller recess. The imaging light mode is set to conventional WLI and subsequently switch to NBI during the procedure, and representative images are collected and preserve for further analysis. All lesions, detected by either WLI or NBI, are biopsied.
Study NCT00903656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicinhydrochloride, Lapatinib
Description: Lapatinib 1250mg/d p.o. Caelyx 40 mg/m² i.v. q4w for a maximum of 6 cycles
Study NCT04423354 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert Type Ⅱ Adenocarcinoma of Esophagogastric Junction
Description: Patients diagnosed with Siewert Ⅱ adenocarcinoma of esophagogastric junction and met the inclusion criteria will be assigned to the research group and carry out transthoracic single-hole assisted laparoscopic radical gastrectomy by the fixed surgical group.The same model surgical instruments will be provided by the same instrument company.
Study NCT02244996 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycium Barbarum
Description: Traditional Chinese Herbs
Study NCT02244996 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02038920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV injection
Study NCT02038920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab placebo
Description: Vedolizumab placebo-matching IV infusion
Study NCT01798277 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: Catheter ablation of ventricular tachycardia will employ three-dimensional mapping Fast Anatomical Mapping or CARTOSOUND technology (Biosense Webster Inc.), and the Thermocool Navistar catheter (Biosense Webster Inc.).
Study NCT01798277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical therapy (sotalol or amiodarone)
Description: Patients will be tiered to one of two possible antiarrhythmic drugs (sotalol or amiodarone).
Study NCT04829929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omega™LAA Occluder implantation
Description: Left Atrial Appendage closure for patients with non-valvular atrial fibrillation (NVAF) and high bleeding risk by Omega™LAA Occluder using Omega™ Delivery System
Study NCT02729623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kite Systems cannaHALER cannabis Inhaler.
Study NCT01998009 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fecal occult blood tests
Study NCT02561533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BRAF detection on fine needle aspiration biopsy (FNAB)
Study NCT00724308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Care Coordination
Description: The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from TeleQuit MH study counselors; and (4) follow-up at 2 and 6 months to check the patient's smoking status.
Study NCT00724308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Care Coordination with state Quitline
Description: The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from the patient's state Quitline; and (4) follow-up at 2 and 6 months to check the patient's smoking status.
Study NCT03459014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulus rich VE
Description: Participants will walk in the Lokomat with the VR for 21 minutes. After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).
Study NCT03459014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stimulus poor VE
Description: Participants will walk in the Lokomat with the VR for 21 minutes. After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).
Study NCT04530331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: Dietitians visited the worksites of the intervention group once a week to deliver a nutrition education session and provide dietary advice for each participant.
Study NCT03701867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metabolic Flexibility Tests
Description: Energy Metabolism, Oxygenation, Body Composition, Blood Samples
Study NCT01912456 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-volume C1-esterase inhibitor
Study NCT01912456 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Higher-volume C1-esterase inhibitor
Study NCT01912456 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-volume placebo
Study NCT01912456 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Higher-volume placebo
Study NCT01340196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir/BI 201335
Description: tenofovir medium dose once daily (qd) for first 15 days; BI 201335 medium dose twice daily (bid) on days 8 through 22 with last dose on morning of day 22